Late-breaking research results for Acute Lymphoblastic Leukemia (ALL)
#leukemia #drugstudies #cancerresearch #cancerrelapse #cancerimmunotherapy #bloodcancer #immunotherapy #blinatumomab #fdaapproved #chemotherapy
Late-breaking research reveals a major treatment advance for adults with newly diagnosed B lineage acute lymphoblastic leukemia (ALL). The randomized phase 3 study E1910 evaluated blinatumomab immunotherapy in patients with a good prognosis after an initial round of chemotherapy. After about 3.5 years of follow-up, 83% of the patients who went on to receive additional standard consolidation chemotherapy plus experimental blinatumomab were alive versus 65% of those who received chemotherapy only.
Blinatumomab is a "targeted" drug that directs a patient's T cells (part of the immune system) to recognize malignant B cells and destroy them. It has two FDA approvals for patients with B lineage ALL: those with relapsed/refractory disease (approved in 2014) and those in first or second complete remission who test positive for MRD at more than 0.01% (approved 2018).
Get the latest medical and health news at medicaldialogues.in
Follow us on
Twitter: https://twitter.com/medicaldialogs
Facebook: https://www.facebook.com/medicaldialogues/
Instagram: https://www.instagram.com/medicaldialogues
LinkedIn: https://www.linkedin.com/company/medical-dialogues
Website: https://medicaldialogues.in/
-
Category
No comments found